Glenn J. Hanna

This study is testing a new immune therapy called RP2, made from a modified herpes virus, to treat high-risk oral precancerous conditions and prevent them from turning into oral cancer. The therapy is injected directly into the lesion. The trial will enroll 25 people and look at …